Sanofi (NASDAQ:SNY) Trading 4% Higher - Still a Buy?

Sanofi (NASDAQ:SNY - Get Free Report) traded up 4% during trading on Monday . The company traded as high as $56.81 and last traded at $56.63. 3,034,498 shares traded hands during trading, an increase of 26% from the average session volume of 2,403,886 shares. The stock had previously closed at $54.47.

Analyst Ratings Changes

A number of research firms recently weighed in on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Sanofi currently has an average rating of "Buy" and a consensus price target of $60.00.

Sanofi Stock Performance

The firm has a fifty day simple moving average of $52.00 and a 200-day simple moving average of $52.64. The stock has a market cap of $150.10 billion, a price-to-earnings ratio of 23.76, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its holdings in Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after acquiring an additional 33,105 shares during the period. Arkadios Wealth Advisors boosted its position in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after purchasing an additional 751 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. increased its holdings in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, Kentucky Trust Co acquired a new position in Sanofi in the fourth quarter valued at about $436,000. Institutional investors and hedge funds own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.